Quick episode summary

John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more.

• Welcome to the Eyeluminaries podcast :00
• Review of episode 20 1:16
• Intro of Eric D. Donnenfeld, MD 2:06
• Understanding the role of private equity: where does it stand and where is it going? 4:22
• Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19
• What are the technologies that you are most excited about? 8:17
• What are the things to watch out for? 11:08
• Do you have an interesting James Worthy story? 13:34
• Intro of Calvin C. Roberts, MD 15:21
• Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48
• How does a chief medical officer work within a company? 18:56
• How is what ARPA-H doing different than simply transplanting an eye? 20:42
• Intro of Mark L. Baum 26:06
• What does the rebranding of the company mean? 27:00
• Pharmaceutical names: VEVYE 28:22
• How will you market VEVYE in the US? 29:48
• Fortisite 31:59
• What is the future of the company? 32:47
• What do you think of Dr. Wiley Chambers’ retirement? 34:09
• Intro of Jeannette Bankes 36:51
• Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16

·       If you could change anything in the ophthalmic industry, what would it be? 42:53

·       How excited are you about robotics? 44:06

·       Tell us about your promotion 44:52

·       How can we develop a more diverse leadership in ophthalmology? 45:31

• Preview of episode 22 48:01
• Feedback, questions and guest suggestions at [email protected] 48:18

 

Jeannette Bankes is the president and general manager of global surgical franchises for Alcon.

Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow.

Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision.

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H.

We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.